Cognitive outcomes of the bipolar depression electrical treatment trial (BETTER): a randomized, double-blind, sham-controlled study.
Cognitive outcomes of the bipolar depression electrical treatment trial (BETTER): a randomized, double-blind, sham-controlled study.
复制标题
双相抑郁症电治疗试验（BETTER）的认知结果：一项随机、双盲、假对照研究。
DOI：
10.1007/s00406-020-01121-2
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Brunoni,And
中科院分区：
文献类型：
--
作者：
Tortella,Gabriel;Sampaio-Junior,Bernardo;Moreno,MarinaL;Moffa,AdrianoH;daSilva,AdrianoFernandes;Lafer,Beny;Lotufo,PauloAndrade;Gattaz,Wagner;Borrione,Lucas;Machado-Vieira,Rodrigo;Goerigk,Stephan;Benseñor,IsabelaM;Brunoni,And
双相抑郁症与明显的认知缺陷有关。这种情况的药物治疗是有限的，可能会加重抑郁和认知症状。因此，有必要进行治疗干预，以保持足够的认知功能。我们之前的研究结果表明，在双相抑郁电治疗试验（BETTER）中，经颅直流电刺激（tDCS）具有显著的临床疗效。在这里，本研究的认知结果报告。我们将59例双相情感障碍I型或II型急性抑郁发作患者随机分为两组，分别接受主动（12 2 mA，30 min，阳极-左，阴极-右前额叶皮层tDCS治疗）或假tDCS治疗。患者接受稳定的药物治疗方案至少2周。在基线、两周后和终点（第6周），对5个认知领域（注意力和处理速度、记忆、语言、抑制控制、工作记忆和执行功能）进行了一组12项神经心理学评估。在6周治疗期间，未观察到任何认知结局的组间显著差异。此外，未观察到认知表现下降。我们的发现值得在更大规模的研究中进一步复制。试验注册：clinicaltrials.gov标识符：NCT 02152878
Bipolar depression is associated with marked cognitive deficits. Pharmacological treatments for this condition are limited and may aggravate depressive and cognitive symptoms. Therefore, therapeutic interventions that preserve adequate cognitive functioning are necessary. Our previous results demonstrated significant clinical efficacy of transcranial direct current stimulation (tDCS) in the Bipolar Depression Electrical Treatment Trial (BETTER). Here, cognitive outcomes of this study are reported. We randomized 59 patients with bipolar disorder I or II in an acute depressive episode to receive active (12 2 mA, 30-min, anodal-left, cathodal-right prefrontal cortex tDCS sessions) or sham tDCS. Patients were on stable pharmacological regimen for at least 2 weeks. A battery of 12 neuropsychological assessments in five cognitive domains (attention and processing speed, memory, language, inhibitory control, and working memory and executive function) was performed at baseline, after two weeks and at endpoint (week 6). No significant differences between groups over 6 weeks of treatment were observed for any cognitive outcomes. Moreover, no decrease in cognitive performance was observed. Our findings warrant further replication in larger studies.Trial Registration:clinicaltrials.gov Identifier: NCT02152878